The Genomic Advances in Sepsis (GAinS) study has been recruiting intensive care patients with sepsis for further study for over a decade. The project was initiated by the UK Critical Care Genomics group in 2005 to characterise genetic variants that affect susceptibility to and outcomes from sepsis. Sepsis is a life-threatening complication of infection caused by a dysregulated host immune response leading to organ failure. It affects an estimated 30 million people worldwide each year, and is recognised as a global health priority by the World Health Organisation. Over 2000 patients with sepsis have been enrolled to the GAinS study with a recent exciting collaborative opportunity with Genomics England, recruiting patients to the 100,000 genomes project. Current work uses a multi-omics approach to explore the sepsis response and the GAinS researchers have recently launched a new website for both patients/relatives and researchers to describe their ongoing work.
The Genomic Advances in Sepsis (GAinS) study launches new website
5 February 2019
